Treatment Uses Reduced-Intensity Preconditioning to Enhance Its Global Transportability
After over a decade of preclinical research and development, a new gene therapy treatment for sickle cell anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.
Preliminary data from a pilot Phase 1-2 clinical trial testing the gene-addition therapy were presented Dec. 3 at the American Society of Hematology’s (ASH) annual meeting in San Diego by principal investigator Punam Malik, MD. She is a physician-scientist at the Cincinnati Children’s Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center. Malik called the data promising.
“One year after treatment of our first patient, and six months after treatment of our second patient, both have seen a remarkable improvement in the quality of life due to remarkable reduction in disease symptoms. This includes near elimination of chronic pain and sickling events and improved anemia,” Malik said. “Although it’s still early post-treatment, these preliminary results are quite promising. If sustained this therapy will provide a transportable, safe and feasible gene therapy for all SCA patients.”
SCA is a painful, inherited disease where blood cells become sickle-shaped and stuck in the vascular system. It can damage vital organs and cause death.
How the Therapy Works
The gene therapy developed by Cincinnati Children’s uses a modified gamma globin lentivirus vector to transfer a healthy fetal hemoglobin gene into a patient’s blood stem cells (hematopoietic stem cells, HSC). The lentivirus is modified so it does not cause illness.
The therapy comes from the observation that some adults never stop producing fetal hemoglobin (HbF). This prevents red blood cell sickling when sufficient quantities of HbF are present in the body. Normally, the fetal hemoglobin gene switches off shortly after birth. The new gene therapy approach designed by Malik and team places a fetal hemoglobin gene in the bone marrow cells that cannot switch off.
Cells are collected earlier from the SCA patient and genetically reprogrammed in a clean lab facility with the modified lentivirus vector. Then the patient’s bone marrow is preconditioned with one low-dose of chemotherapy, after which the gene-corrected cells are infused back into the patient. Patients recover their blood counts within a week to 10 days and recover from the chemotherapy effects by two weeks, Malik said.
A key feature of the treatment regimen is the reduced-intensity preconditioning for patients receiving the therapy for SCA. The method is less toxic and expensive than myeloablative preconditioning normally used in bone marrow transplants, according to the researchers.
Myeloablative conditioning uses high-intensity chemotherapy to prepare a transplant patient’s bone marrow for healthy gene-corrected blood stem cells (HSCs). This typically results in low blood counts and other side effects. These can include severe infections and long stays in transplant units for one or two months.
This means transplants using myeloablative conditioning have to be performed at large and sophisticated medical centers in developed parts of the world. Malik said this limits access to people in underdeveloped regions where SCA is more common, like Africa, India, the Caribbean and South America.
Reaching High-Need Regions
One goal for Malik and her colleagues is that their therapy’s reduced intensity conditioning will allow it to be offered at hospitals in places like Central Africa and other underdeveloped regions of the world.
SCA affects more than 90,000 people in the United States, and millions of people worldwide have the disease, according to the researchers.
Malik said additional data from the study will tell investigators of the consistent and long-term clinical benefit of this therapy to patients with severe SCA. The trial is scheduled to treat up to 10 patients with SCA. Preclinical studies by the research team suggested the treatment allows the body to produce normal red blood cells instead of the sickle-shaped cells that define the inherited disorder.
Improved Quality of Life
Both adult patients included in the ASH presentation are 35 and 25 years old who, respectively, had gene transfer therapy 15 and 12 months ago. In the year and a half prior to receiving gene-correction therapy, both patients had more than a dozen acute sickle events per year, according to Malik. These included acute chest and pain crises, chronic pain, and required the ongoing use of oral or injectable opioids on a regular basis.
Investigators report that one year following therapy, the first patient no longer requires daily oral opioids for chronic pain and has had one acute sickle cell event. The second patient no longer uses oral opioids and has no vaso-occlusive events, where blood cells become stuck in the vascular system.
The Latest on: Sickle cell anemia
via Google News
The Latest on: Sickle cell anemia
- Advanced machine used to check sickle cell patients on December 16, 2018 at 2:21 pm
The weeklong programme involved giving information and busting myths about sickle cell anaemia, a hereditary disease. Patients, either sufferers or carriers of the disease, were invited to lectures. […]
- Gene therapies could transform sickle cell disease into a curable illness on December 13, 2018 at 6:28 am
It helped usher in the modern era of medicine, focused on using the biological roots of illness to unravel disease - and yet, sickle cell anemia, which is most common in people of African descent, has ... […]
- Giving Life to Indigent Sickle Cell Carriers on December 12, 2018 at 5:52 pm
The Omotoke Gambari Foundation recently reached out to 63 children living with sickle cell anemia with the aim of celebrating them despite their health challenges and indigent situation. Sunday Ehigia... […]
- Bipartisan Support: Senators Cory Booker and Tim Scott just got a law passed to help fight sickle cell disease on December 12, 2018 at 4:54 pm
Ninety percent of those who are diagnosed with sickle cell are African-American. Sickle cell anemia is group of blood disorders which cause infections, pain and fatigue, making everyday life ... […]
- In Africa, Sickle Cell Patients Endure Pain, Discrimination on December 12, 2018 at 8:33 am
Africans who have the blood disorder sickle cell anemia met this week in the northern Cameroon town of Garoua to step up an awareness campaign. One hundred people with sickle cell from Cameroon and fi... […]
- Sickle Cell Anemia Treatment Safely Lowers Disease Burden in African Children on December 7, 2018 at 4:56 am
CINCINNATI: A daily hydroxyurea pill may finally bring some relief for young children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Afric... […]
- Early clinical trial data show gene therapy reversing sickle cell anemia on December 5, 2018 at 8:38 am
After over a decade of preclinical research and development, a new gene therapy treatment for sickle cell anemia (SCA) is reversing disease symptoms in two adults and showing early potential for trans... […]
- Global Sickle-Cell Anemia Therapeutics Market Analysis & Forecast (2018-2025) - ResearchAndMarkets.com on December 5, 2018 at 7:28 am
DUBLIN--(BUSINESS WIRE)--The "Global Sickle-Cell Anemia Therapeutics Market Analysis 2018 - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The report contains up to ... […]
- Sickle Cell Gene Therapy Makes Another Advance on December 4, 2018 at 1:55 pm
TUESDAY, Dec. 4, 2018 (HealthDay News) -- A new gene therapy shows early promise against sickle cell anemia, researchers say. The therapy targets the genetic flaw that causes sickle cell. In a small g... […]
via Bing News